Anesthesia
Conditions
Keywords
low flow anesthesia, wash-in, sevoflurane
Brief summary
The investigators propose a new wash-in technique for sevoflurane low flow anesthesia with fresh gas flow of O2:N2O or O2:air 1:1 L/min with sevoflurane 8%. The objective of this study is to identify time to achieve alveolar concentration of sevoflurane at 1, 1.5, 2, 2.5, 3, and 3.5%
Detailed description
The benefits of low flow anesthesia are economic, less pollution, more heat and humidity preservation but it requires appropriate wash-in phase. The current wash-in protocols for sevoflurane are complicated and time consuming. The investigators propose a new 1-1-8 sevoflurane wash-in protocol which is more simple and predictable. The objective of this study is to identify time to achieve alveolar concentration of sevoflurane at 1, 1.5, 2, 2.5, 3, and 3.5% with 1-1-8 wash-in protocol. All patients will receive iv propofol 2 mg/kg as induction agent and succinyl choline 1.5 mg/kg for intubation. Then the ventilation will be controlled to achieve end-tidal CO2 30-35 mmHg with O2:N2O or O2:air 1:1 L/min with sevoflurane 8%. Time to achieve alveolar concentration of sevoflurane at 1, 1.5, 2, 2.5, 3, and 3.5% will be recorded and analyzed. After that, the concentration of sevoflurane and anesthetic technique will be adjusted to requirement of anesthesiologist.
Interventions
PROCEDURE1-1-8 wash-in
wash-in phase during start of low flow anesthesia
DRUGSevoflurane
Drug used for wash-in protocol
Sponsors
Khon Kaen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All participants will receive sevoflurane 8% with O2:N2O or O2:air 1:1 L/min under controlled ventilation. Time to achieve alveolar concentration of sevoflurane of 1%, 1.5%, 2%, 2.5%, 3% and 3.5% will be recorded.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* ASA classification I-II * age 18-65 years
Exclusion criteria
* BMI \> 35 * contraindicated for N2O * • with pulmonary or cardiac disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time | participants will be followed until alveolar concentration of sevoflurane reaches 3.5%, as expected of 10 minutes | Time (in second) to achieve alveolar concentration of sevoflurane 1, 1.5, 2, 2.5, 3, and 3.5% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate | participants will be followed until alveolar concentration of sevoflurane reaches 3.5%, as expected of 10 minutes] | Heart rate (beat/min) at alveolar concentration of sevoflurane of 1, 1.5, 2, 2.5, 3 and 3.5% |
| Blood pressure | participants will be followed until alveolar concentration of sevoflurane reaches 3.5%, as expected of 10 minutes] | Blood pressure (systolic and diastolic (mmHg)) at alveolar concentration of sevoflurane of 1, 1.5, 2, 2.5, 3 and 3.5% |
Countries
Thailand
Outcome results
None listed